Beese Fulmer Investment Management Inc. Has $471,000 Stake in Stryker Co. (SYK)
Beese Fulmer Investment Management Inc. held its position in shares of Stryker Co. (NYSE:SYK) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 3,394 shares of the medical technology company’s stock at the end of the second quarter. Beese Fulmer Investment Management Inc.’s holdings in Stryker were worth $471,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Baystate Wealth Management LLC boosted its stake in Stryker by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares in the last quarter. James Investment Research Inc. bought a new stake in Stryker during the second quarter valued at about $155,000. Guardian Life Insurance Co. of America boosted its stake in Stryker by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares in the last quarter. Assetmark Inc. boosted its stake in Stryker by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares in the last quarter. Finally, Mosaic Family Wealth LLC boosted its stake in Stryker by 3.5% in the first quarter. Mosaic Family Wealth LLC now owns 1,300 shares of the medical technology company’s stock valued at $171,000 after buying an additional 44 shares in the last quarter. Institutional investors and hedge funds own 74.16% of the company’s stock.
Stryker Co. (SYK) traded down 0.1935% during mid-day trading on Tuesday, hitting $139.2999. 181,069 shares of the company were exchanged. The stock’s 50 day moving average is $144.80 and its 200-day moving average is $137.03. The company has a market cap of $52.11 billion, a price-to-earnings ratio of 31.0937 and a beta of 0.80. Stryker Co. has a 12-month low of $106.48 and a 12-month high of $148.84.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.51 by $0.02. Stryker had a return on equity of 15.89% and a net margin of 12.98%. The business had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same period in the prior year, the company earned $1.39 EPS. Stryker’s revenue for the quarter was up 6.1% on a year-over-year basis. Equities research analysts predict that Stryker Co. will post $6.47 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Investors of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.22%. Stryker’s dividend payout ratio is currently 37.95%.
Several analysts recently issued reports on the stock. Stifel Nicolaus upped their price target on shares of Stryker from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. BidaskClub cut shares of Stryker from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Stryker in a report on Tuesday, May 16th. They issued a “neutral” rating and a $129.00 price target on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 price target (down from $158.00) on shares of Stryker in a report on Thursday, August 24th. Finally, Argus reaffirmed a “buy” rating and issued a $160.00 price target on shares of Stryker in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $145.73.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now directly owns 88,207 shares in the company, valued at approximately $12,909,976.52. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,810 shares of company stock valued at $4,754,958. 7.40% of the stock is owned by corporate insiders.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.